Delivery Order SPE2DB20D2104-SPE2DB25FMSHG
- Not listed
- The Defense Logistics Agency awarded a $6,378.11 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded pharmaceutical procurement. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This contract, valued at $11,831.54, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The order is scheduled for ultimate completion by June 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $53,908.10 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,096.32 and is scheduled for completion by August 1, 2025. The place of performance is listed as the contractor's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $16,491.43 and an ultimate completion date of September 29, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $35,151.10 to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for completion by November 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,788.22 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed-price, non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This competitive award, valued at $11,159.05 under a firm fixed-price contract type, is scheduled for completion by August 25, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, indicating it was...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $55,124.14 and an ultimate completion date of August 29, 2025. The contract involves no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units) with a ceiling value of $36,293.07. This firm fixed-price delivery order, with an ultimate completion date of August 22, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen Drug...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMSHGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,734.88 on June 2, 2025, for the supply of Biktarvy 50-200-25 mg tablets in a quantity of 30 units. This is a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical supply vehicle enables AmerisourceBergen to deliver a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract supports critical federal healthcare needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with the company demonstrating consistent capability to fulfill federal procurement requirements across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 6/2/25 |